Kirsten Bibbins-Domingo at the University of California San Francisco, was the lead author.
VOA: special.2010.01.27
The question used to shape the draft recommendations, which were posted online Tuesday, is whether hormone therapy should be used by menopausal women to prevent a hypothetical future health event such as heart disease or cognitive decline, Bibbins-Domingo said.
"These are women who don't have disease, who don't have menopause symptoms, who are using the therapies only to prevent something that might happen in the future, " said Bibbins-Domingo, an associate professor of medicine, epidemiology and biostatistics at the University of California, San Francisco.